The Penn State Research Foundation

Anacor Pharmaceuticals, Inc.

Scripps Clinic and Research Foundation

The Pennsylvania Research Corporation

Other

The Scripps Research Institute

Research, Incorporated

Cold Spring Harbor Laboratory

The Pennsylvania State University

Stephen J Benkovic

Frank Salinas

Yong-Kang Zhang

Tsutomu Akama

Kirk R Maples

Stephen J Baker

Jacob J Plattner

Ving J Lee

Vittorio A Sauro

Chunyu Liu

Richard A Lerner

Rajeshwar Singh

Carolyn Bellinger-Kawahara

Kenneth Charles Keiler

Alfonso Tramontano

Andrew D Napper

Vincent S Hernandez

Virginia J Sanders

Michael Richard Kevin Alley

George Yiannikouros

Marc Alan Ostermeier

Karin M Hold

Fernando Rock

Huchen Zhou

Igor Likhotvorik

Zhuoyi Su

Zhixiang Yang

Nicholas Winograd

Michael DiPierro

Isaac Kennedy

Aaron M Stemphoski

Weimin Mao

John W Tomsho

Chetan Pandit

Charles P Scott

Ernesto V Abel-Santos

Stefan Lutz

Andrew E Nixon

Paul R Schimmel

Nicholas K Tonks

Tony Jun Huang

Craig P Stephens

Siead Zegar

Anthony J Berdis

Navasona Krishnan

Elizabeth D Getzoff

Lucy Shapiro

Irene H Lee

Irene N Lee

Scott D Putney

Siead Zagar

Chun Yu Liu

Rajesjwar Singh

Daniel Ahmed

Chunliang Liu

Ali Tavassoli

Rachel Wright

Lyn Sue Kahng

James Inglese

Richard A Blatchly

Richard A Gibbs

Scott D Taylor

Victoria A Roberts

Edward Q Kaiser

John A Tainer

Christopher L Brummel

A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R, R, Rand Rare defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.

Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase

Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, includingand other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vive by the addition of the peptides.

Antibacterial and plasmid elimination agents

A latex paint composition that contains a film-forming binder and pigment dispersed in an aqueous vehicle and also contains an effective amount of one or more cellulose-supportable fungus growth-inhibiting benzoxaborole compounds of Formula C is disclosed. A method of using that latex paint to inhibit the growth of a cellulose-supportable fungus on a cellulosic surface is also disclosed, as is a method of inhibiting such growth by painting over an fungus-infected surface with a contemplated latex paint.

Benzoxaborole-containing coating resistant to cellulose-supportable fungus

An anti-fungal composition for the control of one or more target fungi (or a similar heterotrophic, hyphae-producing organism) that infect plant materials and are(is) separately controllable by a benzoxaborole and an anti-fungal compound of a preselected FRAC Target Site Code is disclosed, as is a method of its use. A composition contains a diluent medium having dissolved or dispersed therein a synergistic effective amount of each of a first and a second anti-fungal compound. The first anti-fungal compound is a benzoxaborole of Formula I. The second anti-fungal compound is other than a benzoxaborole and is known to control said one or more target species of fungus when utilized as the sole anti-fungal compound at a concentration greater than the synergistic effective amount and has a preselected FRAC Target Site Code of B, C, D, E, G, H, or M.

Synergistic benzoxaborole-containing anti-fungicidal composition

A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor. The recombination intermediate is treated with a high fidelity polymerase to permit the replication and amplification of the target nucleic acid sequence. In preferred embodiments, the polymerase comprises a polymerase holoenzyme. In further preferred embodiments, the recombination factor is bacteriophage T4 UvsX protein or homologs from other species, and the polymerase holoenzyme comprises a polymerase enzyme, a clamp protein and a clamp loader protein, derived from viral, bacteriophage, prokaryotic, archaebacterial, or eukaryotic systems.

Methods for nucleic acid manipulation

Apparatuses and methods for generating a chemical gradient within a flow channel include providing at least one bubble support structure within the flow channel. A bubble support structure helps maintain a bubble at a predetermined location in flow channel when a fluid flow passes therethrough. Oscillations are induced in the bubble using acoustic waves, which may be provided by a piezoelectric transducer located proximate the flow channel. Two or more inlets provide fluids of different chemical compositions into the flow channel, and bubble oscillations are used to generate a dynamically controllable mixing process.

Spatiotemporal control of chemical microenvironment using oscillating microstructures

An anti-fungal composition for the control of one or more target fungi (or a similar heterotrophic, hyphae-producing organism) that infect plant materials and are (is) separately controllable by a benzoxaborole and an anti-fungal compound of a preselected FRAC Target Site Code is disclosed, as is a method of its use. A composition contains a diluent medium having dissolved or dispersed therein a synergistic effective amount of each of a first and a second anti-fungal compound. The first anti-fungal compound is a benzoxaborole of Formula I. The second anti-fungal compound is other than a benzoxaborole and is known to control said one or more target species of fungus when utilized as the sole anti-fungal compound at a concentration greater than the synergistic effective amount and has a preselected FRAC Target Site Code of B, C, D, E, G, H, or M.

Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, includingand other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vivo by the addition of the peptides.

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Boron-containing small molecules

A boronic or borinic acid compound is used to inhibit the activity of a sulfenic acid-containing protein. Thus, a biologically-active sulfenic acid-containing protein is contacted with an activity-inhibiting effective amount of a boronic or borinic acid compound of Formula I or a salt, hydrate or solvate thereof, whose components are disclosed within, and that contact is maintained for a time sufficient to inhibit the biological activity of the protein. 

Boronic and borinic acid compound as inhibitors of sulfenic acid-containing proteins

Growing community of inventors

State College, PA, United States of America

Stephen J Benkovic